Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-317

I still reckon 15 cents is the floor, and it wont go up until after the AGM, as the directors want the share price below the incentive option exercise price of 20 cents before the meeting so it is seen that they are not getting a free kick. The new directors cannot be happy with the share price. It is a reflection of their performance, no matter which way you look at it. The share price was 24 cents before the cap raise with $2m in the can. Now we have $18m, and we are in a reasonable market. I am convinced however that in 6 to 12 months this will be a distant memory, and one we reflect back on as being a significant buying opportunity.